tbuckley/cabot-search huggingface dataset:
A role for FGFR1 in paediatric gliomas
Authors: Naomi Egbivwie, Tracy Warr, Matthew Humphries, Filomena Esteves, Susan Short, Julia Cockle, Anke Brüning-Richardson
Journal: Neuro-Oncology (2018)

Paediatric high-grade gliomas (pHGGs) are highly invasive tumours associated with extremely poor prognosis. There is urgent clinical need to develop novel therapeutic strategies that can target the process of tumour migration and invasion. Fibroblast growth factor receptors (FGFRs) are transmembrane receptor tyrosine kinases associated with glioma tumourigenesis that play a role in regulating cell migration and invasion. An increased frequency of FGFR1 mutations has recently been described in paediatric gliomas (Zhang et al. 2013). Here, the role of FGFR1 in paediatric gliomas was investigated. FGFR1 levels (phosphorylated/unphosphorylated) and cellular localisation were determined by immunofluorescence in two pHGG cell lines (KNS42 and SF188) and five short-term cultures derived from pilocytic astrocytomas (grade 1). FGFR1 activity was stimulated by addition of FGF2. The activity of three FGFR1 inhibitors on cell migration after stimulation was assessed by live cell imaging and in a 3D spheroid invasion assay. FGFR1 levels in low and high-grade paediatric and adult tumour types were investigated in a commercial tissue microarray (TMA). FGFR1 was found to be expressed among all cell lines examined by immunofluorescence. Phosphorylated (activated) FGFR1 was elevated in some cell lines after stimulation with FGF2. Live cell imaging of inhibitor-treated cells and spheroid invasion assays suggest pro-migratory effects of FGFR1 inhibition in low-grade versus anti-migratory in high-grade tumours. High FGFR1 expression in astrocytomas from patients aged under 18 compared to the 18–60 age group (χ2 = 11.578, p = 0.0031) was determined in the TMA sample set. There was a significant association of high FGFR1 levels with grade 2 and 3 astrocytomas. We report the presence of FGFR1 among low and high-grade paediatric gliomas and a role in cell migration after stimulation with ligand. Treatment with FGFR1 inhibitors may elicit a different effect on cell migration depending on tumour grade.
SPECIFIC ACTION OF ATROPIN IN RELIEVING CERTAIN IRREGULARITIES OF HEART BEAT
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Section Registration
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long-term follow-up of health care workers with work-site exposure to human immunodeficiency virus
Authors: K. Henry
Journal: JAMA (1990)

<h3>To the Editor.—</h3> Recently, the issue of risk for human immunodeficiency virus (HIV) infection among health care workers has received heightened attention in both the lay and medical press, with an underlying theme of this renewed concern being a distrust of the current data (<i>Newsweek</i>. November 20, 1989:82-83).<sup>1</sup> Current Centers for Disease Control guidelines are predicated on the observed HIV seroconversion rate of 0.42% seen in studies of health care workers who suffer documented work-site exposure to HIV.<sup>2,3</sup>Health care workers with exposure to body fluids of HIV-infected persons are frequently traumatized emotionally and may be advised to begin prophylaxis with zidovudine.<sup>4</sup> Data such as those reported by Imagawa et al<sup>5</sup>and Haseltine<sup>6</sup>raise the possibility that the false-negative rate of HIV serological testing might be significant in certain populations. Since the Centers for Disease Control recommendations regarding HIV exposure of health care workers were
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2020
Authors: Candice L. Robinson, Henry Bernstein, Katherine Poehling, José R. Romero, Peter Szilagyi
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

At its October 2019 meeting, the Advisory Committee on Immunization Practices (ACIP)* approved the 2020 Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger. The 2020 child and adolescent immunization schedule summarizes ACIP recommendations, including several changes from the 2019 immunization schedule† on the cover page, three tables, and notes found on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules/index.html). Health care providers are advised to use the tables and the notes together. This immunization schedule is recommended by ACIP (https://www.cdc.gov/vaccines/acip/index.html) and approved by the CDC Director, the American Academy of Pediatrics, the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, and, for the first time, the American College of Nurse-Midwives.
STATE TUBERCULOSIS SANATORIA.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Postnatal Development of Vision in Human and Nonhuman Primates
Authors: R. Boothe
Journal: Annual Review of Neuroscience (1985)

The brain's default mode network consists of discrete, bilateral and symmetrical cortical areas, in the medial and lateral parietal, medial prefrontal, and medial and lateral temporal cortices of the human, nonhuman primate, cat, and rodent brains. Its ...Read More
JAMA Oncology
Journal: JAMA Oncology (2016)

JAMA Oncology is committed to publishing infl uential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.Mission Statement JAMA Oncology is the defi nitive journal for scientists, clinicians, and trainees in the fi eld of oncology worldwide.Our original, innovative, and timely scientifi c and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers.JAMA Oncology aims to eff ectively convey the fi ndings of important clinical research, major scientifi c breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community.Our goal is that successful communication of new knowledge will ultimately translate to clinical benefi t for people living with and surviving cancer.
Redesigning Heparin
Authors: Robert D. Rosenberg
Journal: New England Journal of Medicine (2001)

The anticoagulant mechanism of heparin was obscure until 1973,1 when it was found that heparin enhances by as much as 1000 times the ability of the plasma protein antithrombin to form complexes with thrombin, factor Xa, and factor IXa, thereby inhibiting their activity and acting as an anticoagulant. Three years later, Lam et al. showed that only a small fraction of heparin binds to purified antithrombin, yet this fraction possesses virtually all of the anticoagulant activity of heparin.2 The region responsible for the anticoagulant activity of heparin has a unique oligosaccharide structure — the antithrombin-binding domain. Lindahl et al. made . . .
Funding for Biomedical Research—Reply
Authors: Hamilton Moses, E. Ray Dorsey, David H. M. Matheson, Samuel O. Thier
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reinfection with hepatitis C following cure: results from the TraP Hep C program in Iceland - a prospective nationwide, population-based study
Authors: Jon M Johannesson, Sigurdur Olafsson, Ragnheidur H. Fridriksdottir, Thorvardur J. Löve, Valgerdur Runarsdottir, Gudrun Sigmundsdottir, Arthur Löve, Magnús Gottfredsson
Journal: Journal of Hepatology (2020)
Incorrect Unit of Measure and Omitted Grant
Journal: JAMA (2014)

Norrina B. Allen, PhD, MPH; Juned Siddique, DrPH; John T. Wilkins, MD, MS; Christina Shay, PhD; Cora E. Lewis, MD, MSPH; David C. Goff, MD, PhD; David R. Jacobs Jr, PhD; Kiang Liu, PhD; Donald Lloyd-Jones, MD, ScM
Cognitive and Psychomotor Performance Tests and Experiment Design in Multiple Chemical Sensitivity
Authors: Anthony Wetherell
Journal: Environmental Health Perspectives (1997)

People suffering from multiple chemical sensitivity (MCS) complain of a variety of symptoms that could impair cognitive and psychomotor function either directly or indirectly.This paper discusses the use of cognitive and psychomotor performance tests together with some experiment designs that could be considered for use to assess fitness of MCS sufferers for work or the efficacy of diagnostic, preventative, or therapeutic measures.The tests could also contribute to the body of objective information on MCS and help sway the opinion of those who are dubious of its authenticity.The credentials of cognitive and psychomotor performance tests are derived from their successful use in studying the effects of drugs, and the types of tests are illustrated by describing those used by the United Kingdom Defence Evaluation and Research Agency Chemical and Biological Defence Human Studies Group, which has been involved in the assessment of drugs and chemicals on work performance for many years.The tests include mathematical, verbal and spatial processing, tracking, reaction time, attention and vigilance, and memory tests.The discussion of experiment designs includes both repeated measures and parallel groups designs together with their advantages and disadvantages and some suggested modifications to accommodate the particular problems posed by MCS. -
Temporal Variations in School-Associated Student Homicide and Suicide Events—United States, 1992-1999
Journal: JAMA (2001)

Recent, widely reported violent deaths associated with schools have led many adults to believe that a school shooting could occur in their community and many children to express increasing concern about their own safety at school. CDC, in collaboration with the U.S. Education and Justice departments, has been tracking school-associated violent deaths since the 1992-1993 school year. To evaluate whether the risk for school-associated violent death varies during the school year, CDC analyzed monthly counts of school-associated homicide and suicide events that occurred among students in elementary and secondary (middle, junior high, and senior high) schools in the United States. This report summarizes the results of these analyses, which indicate that student homicide event rates are usually highest near the start of the fall and spring semesters, and suicide event rates are highest during the spring semester. These findings can assist school personnel in planning and implementing violence-prevention programs.
Archives of Physical Medicine, Chicago
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the Food and Drug Administration
Authors: S. L. Nightingale
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 162: ASB13 inhibits breast cancer progression and metastasis through SNAI2 degradation and transcriptional regulation of YAP
Authors: Huijuan Fan, Xuxiang Wang, Wenyang Li, Minhong Shen, Yong Wei, Hanqiu Zheng, Yibin Kang
Journal: Cancer Research (2019)

Abstract Metastasis is responsible for the majority of cancer-related deaths. The transcription factor SNAI2 promotes metastasis by facilitating tumor cell invasion and tumor initiating activity. However, its post-translational regulation is less studied. We performed a dual luciferase-based, genome-wide E3 ligase siRNA library screening and identified ASB13 as an E3 ubiquitin ligase that targets SNAI2 for ubiquitination and degradation. ASB13 knockout in breast cancer cells leads to increased cell migration and decreased F-actin polymerization; while overexpression of ASB13 suppresses lung metastasis formed by LM2 cells. Furthermore, we discovered that ASB13 knockout decreases YAP expression, which is dependent on increased SNAI2 protein level. YAP functions as a tumor suppressor gene in breast cancer, as YAP knockout increases tumorsphere formation, anchorage-independent colony formation, and cell migration. Clinical data analysis reveals that ASB13 expression is positively correlated with overall survival in breast cancer patients. These findings establish the ASB13-SNAI2-YAP axis as a regulatory mechanism for breast cancer migration and metastasis. Citation Format: Huijuan Fan, Xuxiang Wang, Wenyang Li, Minhong Shen, Yong Wei, Hanqiu Zheng, Yibin Kang. ASB13 inhibits breast cancer progression and metastasis through SNAI2 degradation and transcriptional regulation of YAP [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 162.
Discussing Do-Not-Resuscitate Status
Authors: Charles F. von Gunten
Journal: Journal of Clinical Oncology (2001)

Article Tools THE ART OF ONCOLOGY: WHEN THE TUMOR IS NOT THE TARGET Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.5.1576 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11230503 Discussing Do-Not-Resuscitate Status Charles F. von GuntenxCharles F. von GuntenSearch for articles by this author Show More From the Center for Palliative Studies, San Diego, CA. https://doi.org/10.1200/JCO.2001.19.5.1576 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology
Cancer Undefeated
Authors: John C. Bailar, Heather L. Gornik
Journal: New England Journal of Medicine (1997)

Despite decades of basic and clinical research and trials of promising new therapies, cancer remains a major cause of morbidity and mortality. We assessed overall progress against cancer in the United States from 1970 through 1994 by analyzing changes in age-adjusted mortality rates.We obtained from the National Center for Health Statistics data on all deaths from cancer and from cancer at specific sites, as well as on deaths due to cancer according to age, race, and sex, for the years 1970 through 1994. We computed age-specific mortality rates and adjusted them to the age distribution of the U.S. population in 1990.Age-adjusted mortality due to cancer in 1994 (200.9 per 100,000 population) was 6.0 percent higher than the rate in 1970 (189.6 per 100,000). After decades of steady increases, the age-adjusted mortality due to all malignant neoplasms plateaued, then decreased by 1.0 percent from 1991 to 1994. The decline in mortality due to cancer was greatest among black males and among persons under 55 years of age. Mortality among white males 55 or older has also declined recently. These trends reflect a combination of changes in death rates from specific types of cancer, with important declines due to reduced cigarette smoking and improved screening and a mixture of increases and decreases in the incidence of types of cancer not closely related to tobacco use.The war against cancer is far from over. Observed changes in mortality due to cancer primarily reflect changing incidence or early detection. The effect of new treatments for cancer on mortality has been largely disappointing. The most promising approach to the control of cancer is a national commitment to prevention, with a concomitant rebalancing of the focus and funding of research.
DEFENSE OF OPIUM EATING.
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal